Nuvation Bio Inc. Class A Common Stock
Price
Key statistics
- Forward rate
- $0.00
- Yield
- 0.00%
- Payout ratio
- 0.00%
- Frequency
- Unknown
Nuvation Bio Inc. Class A Common Stock represents ownership in Nuvation Bio, a global oncology company focused on developing differentiated therapeutic candidates for difficult-to-treat cancers. The company’s current work centers on advancing a portfolio of oncology programs that includes targeted therapies, brain-penetrant inhibitors, and drug-drug conjugate candidates designed to address unmet needs across several cancer types. Its pipeline spans areas such as non-small cell lung cancer, gliomas, and other solid tumors, reflecting a research and development model built around precision medicine and novel mechanisms of action. Nuvation Bio operates as a biopharmaceutical business within the healthcare sector, where it contributes to the broader oncology market through clinical-stage drug development and scientific innovation.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. David T. Hung M.D.
- Employees
- 305
- Headquarters
- New York, NY, United States
- Website
- www.nuvationbio.com